Physician profile
Carlos Solis
NPI 1922657584
$1,708.89
in general payments reported to CMS, 2019-2025
12 companies · $738 in 2025
The $738 reported for 2025 was more than what 83% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $107 · 2022: $37.13 · 2023: $435 · 2024: $391 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,564.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $573.68 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.35 | 2021-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $207.83 | 2021-2025 | Zerbaxa, Dificid, Recarbrio |
| Alexion Pharmaceuticals, INC. | $142.84 | 2023-2025 | Ultomiris, Soliris |
| Mallinckrodt Hospital Products INC. | $108.15 | 2024-2025 | Terlivaz |
| Takeda Pharmaceuticals U.S.A., INC. | $99.80 | 2021-2025 | Livtencity |
| Eisai INC. | $97.57 | 2021-2023 | |
| Madrigal Pharmaceuticals | $81.43 | 2024-2025 | Rezdiffra, Resmetirom |
| Baxter Healthcare | $74.63 | 2025 | Perclot |
| Genentech USA, INC. | $45.98 | 2025 | Tecentriq |
| La Jolla Pharmaceutical Company | $28.80 | 2025 | Giapreza |
| Pacira Pharmaceuticals Incorporated | $25.83 | 2025 | Exparel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Solis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.